| 000 | 01754 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250518055718.0 | ||
| 264 | 0 | _c20210520 | |
| 008 | 202105s 0 0 eng d | ||
| 022 | _a1463-1326 | ||
| 024 | 7 |
_a10.1111/dom.13862 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKoomen, Jeroen V | |
| 245 | 0 | 0 |
_aExposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial. _h[electronic resource] |
| 260 |
_bDiabetes, obesity & metabolism _c01 2020 |
||
| 300 |
_a30-38 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aCardiovascular Diseases _xchemically induced |
| 650 | 0 | 4 |
_aClopidogrel _xpharmacokinetics |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xdrug therapy |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHeart Disease Risk Factors |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOxazoles _xpharmacokinetics |
| 650 | 0 | 4 |
_aPPAR alpha _xagonists |
| 650 | 0 | 4 |
_aPPAR gamma _xagonists |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aThiophenes _xpharmacokinetics |
| 700 | 1 | _aHeerspink, Hiddo J L | |
| 700 | 1 | _aSchrieks, Ilse C | |
| 700 | 1 | _aSchwartz, Gregory G | |
| 700 | 1 | _aLincoff, A Michael | |
| 700 | 1 | _aNicholls, Stephen J | |
| 700 | 1 | _aSvensson, Anders | |
| 700 | 1 | _aWedel, Hans | |
| 700 | 1 | _aWeichert, Arlette | |
| 700 | 1 | _aGrobbee, Diederick E | |
| 700 | 1 | _aStevens, Jasper | |
| 773 | 0 |
_tDiabetes, obesity & metabolism _gvol. 22 _gno. 1 _gp. 30-38 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/dom.13862 _zAvailable from publisher's website |
| 999 |
_c30060562 _d30060562 |
||